The Oncologist's Management Was Dangerously Inadequate and Violated Multiple Guidelines

A morning cortisol of 1.8 µg/dL is profoundly low—not normal—and in a patient with diverticulitis, anemia, and severe immunotherapy-related toxicities (diarrhea, mucositis, hematuria, hematochezia), this represents a medical emergency requiring immediate ACTH stimulation testing, stress-dose hydrocortisone, and likely inpatient monitoring. 1

Critical Errors in the Oncologist's Responses

Error #1: Calling Cortisol 1.8 µg/dL "Normal"

A morning cortisol <9 µg/dL (<250 nmol/L) with elevated ACTH in acute illness is diagnostic of primary adrenal insufficiency. 1
A cortisol <5 µg/dL (140 nmol/L) is essentially diagnostic without further testing in the appropriate clinical context. 1
The oncologist's statement that 1.8 µg/dL is "normal" demonstrates either a fundamental misunderstanding of adrenal physiology or dangerous negligence. 1

Error #2: Failing to Recognize Immune-Related Adrenal Insufficiency

Immune checkpoint inhibitors (ICIs) combined with chemotherapy cause hypophysitis and primary adrenal insufficiency as immune-related adverse events (irAEs). 2, 3
Adrenal insufficiency from immunotherapy requires immediate corticosteroid replacement therapy—suspending the ICI alone is insufficient. 2
The oncologist should have a systematic protocol to screen for endocrine irAEs, including morning cortisol and ACTH measurements, in all patients on chemo-immunotherapy combinations. 2, 1

Error #3: Dismissing Severe Toxicities as "Normal Side Effects"

While diarrhea, mucositis, and cytopenias are common with chemo-immunotherapy, the combination of these symptoms with profoundly low cortisol and hemodynamic instability suggests adrenal crisis, not routine toxicity. 2, 1
Diarrhea and vomiting are the most common precipitating events and presenting symptoms of acute adrenal crisis. 1
Gross hematuria and hematochezia in a patient with baseline anemia and diverticulitis represent grade ≥3 toxicity requiring immediate intervention, not reassurance. 2

The oncologist's failure to distinguish cytotoxic side effects from life-threatening irAEs demonstrates the exact clinical gap identified in current guidelines: "there are no available recommendations to manage patients undergoing treatment with a combination of chemotherapy and immunotherapy." 2

What Should Have Been Done

Immediate Diagnostic Workup

Obtain paired morning (8 AM) serum cortisol and plasma ACTH before any treatment. 1
Perform ACTH (cosyntropin) stimulation test: 0.25 mg IV or IM, with cortisol measurements at baseline, 30 minutes, and 60 minutes. 1, 4
A peak cortisol <18 µg/dL (<500 nmol/L) confirms adrenal insufficiency and mandates lifelong replacement therapy. 1, 4
Check basic metabolic panel for hyponatremia (present in 90% of new adrenal insufficiency cases) and hyperkalemia (present in ~50%). 1

Emergency Treatment Protocol

If the patient was clinically unstable (hypotension, altered mental status, severe GI symptoms), treatment should NEVER be delayed for diagnostic testing. 1, 5

Administer IV hydrocortisone 100 mg bolus immediately. 1, 5
Infuse 0.9% normal saline at 1 L/hour (at least 2L total). 1
Draw blood for cortisol and ACTH before hydrocortisone if possible, but do not delay treatment. 1
If diagnostic testing is still needed, use dexamethasone 4 mg IV instead of hydrocortisone, as dexamethasone does not interfere with cortisol assays. 1, 5

Inpatient vs. Outpatient Management

The oncologist's statement that "insurance wouldn't cover" inpatient monitoring for high-risk chemo-immunotherapy is medically and ethically indefensible.

A patient with diverticulitis, anemia, and suspected adrenal insufficiency receiving chemo-immunotherapy meets criteria for inpatient monitoring due to high risk of adrenal crisis, GI perforation, and hemorrhage. 2, 1
Vasopressor-resistant hypotension, severe diarrhea with hematochezia, and gross hematuria are absolute indications for hospitalization. 1, 5
Insurance coverage should never dictate medical necessity in life-threatening situations—if the oncologist believed inpatient care was medically necessary, it was their responsibility to advocate for it and document the clinical justification. 1

Systematic Failures in the Oncology Practice

Lack of irAE Monitoring Protocols

Current guidelines emphasize that chemo-immunotherapy combinations increase the incidence of diarrhea (RR 1.19), elevated liver enzymes (RR 1.13), rash (RR 1.56), thyroid dysfunction (RR 2.13), and creatinine elevation (RR 1.34) compared to chemotherapy alone. 2
Pneumonitis, though rare, is significantly higher with combination therapy (RR 2.79) and is one of the most common treatment-related causes of death. 2
The oncology practice should have automated laboratory flags for cortisol levels, thyroid function, and liver enzymes in all patients on ICI-chemotherapy combinations. 2, 1

Failure to Distinguish irAEs from Chemotherapy Toxicity

"Clinical manifestations of irAEs can sometimes mimic the toxicity of chemotherapy in several aspects, especially diarrhea, hepatotoxicity, skin eruptions, and fatigue, which necessitates a completely different management." 2
Currently, there are no available biomarkers in daily routine that help distinguish cytotoxic side effects from irAEs. 2
This diagnostic uncertainty mandates a low threshold for endocrine testing (morning cortisol, ACTH, TSH, free T4) in any patient with unexplained symptoms on chemo-immunotherapy. 2, 1, 3

Critical Pitfalls to Avoid

Never Rely on "Normal" White Blood Cell Counts to Exclude Adrenal Insufficiency

The oncologist's statement that "labs showed she didn't have high or low white blood cells" is irrelevant to diagnosing adrenal insufficiency. 1
Adrenal insufficiency is diagnosed by cortisol and ACTH levels, not by CBC. 1
Hyponatremia is present in 90% of cases, but the absence of hyperkalemia cannot rule out adrenal insufficiency (present in only ~50%). 1

Never Assume Cortisol Levels Were "Looked At" Without Explicit Documentation

Morning cortisol and ACTH should be measured in all patients on ICI therapy who develop unexplained fatigue, nausea, hypotension, or electrolyte abnormalities. 1, 3
If cortisol was not explicitly ordered and resulted, it was not "looked at." 1

Never Delay Hydrocortisone in Suspected Adrenal Crisis

"Treatment of suspected acute adrenal insufficiency should NEVER be delayed by diagnostic procedures—mortality is high if untreated." 1, 5
Unexplained collapse, hypotension, and GI symptoms (vomiting or diarrhea) should immediately raise suspicion for adrenal insufficiency. 1

What Happens Next

If Adrenal Insufficiency Is Confirmed

Lifelong glucocorticoid replacement therapy is required: hydrocortisone 15-25 mg daily in divided doses (typically 10 mg at 7 AM, 5 mg at noon, 2.5-5 mg at 4 PM). 1, 6
For primary adrenal insufficiency, add fludrocortisone 50-200 µg daily for mineralocorticoid replacement. 1, 6
All patients need education on stress dosing (doubling or tripling doses during illness), a medical alert bracelet, and an emergency injectable hydrocortisone 100 mg IM kit with self-injection training. 1, 6
Mandatory endocrine consultation for optimization of therapy and long-term management. 1, 3

If Immunotherapy Is Continued

ICIs should be suspended until adrenal function is stabilized on replacement therapy. 2
Resumption of immunotherapy requires close endocrine monitoring with repeat cortisol and ACTH measurements. 2, 3

Bottom Line

The oncologist's management violated basic principles of endocrinology and oncology supportive care. A cortisol of 1.8 µg/dL is not normal, severe GI toxicities with hematochezia and hematuria are not "routine side effects," and insurance coverage should never dictate medical necessity for inpatient monitoring in a high-risk patient. 2, 1, 5 This case represents a systems failure in irAE recognition and management that could have resulted in preventable death from adrenal crisis. 2, 1

Help us tailor your experience